TAS-102

You have access
Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral Squamous Cell Carcinoma Cells
KOJI HARADA, TARANNUM FERDOUS and KATSUAKI MISHIMA

Anticancer Research December 2021, 41 (12) 6039-6049; DOI: https://doi.org/10.21873/anticanres.15423
You have access
The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab
HIDEKAZU KURAMOCHI, TAKESHI YAMADA, YOICHIRO YOSHIDA, AKIHISA MATSUDA, HIROHIKO KAMIYAMA, CHIHIRO KOSUGI, KEIICHIRO ISHIBASHI, ATSUKO FUKAZAWA, KEISUKE IHARA, HIROMICHI SONODA, KAZUHIKO YOSHIMATSU, HIROSHI YOSHIDA, SUGURU HASEGAWA, KAZUHIRO SAKAMOTO, HIDEYUKI ISHIDA, KEIJI KODA and On behalf of the TAS CC3 Study Group

Anticancer Research June 2021, 41 (6) 3131-3137; DOI: https://doi.org/10.21873/anticanres.15098
You have access
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer
TETSUO ISHIZAKI, JUNICHI MAZAKI, MASANOBU ENOMOTO, MASATOSHI SHIGOKA, KENTA KASAHARA, TAKAAKI MATSUDO, HIDEAKI KAWAKITA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA

Anticancer Research April 2021, 41 (4) 2157-2163; DOI: https://doi.org/10.21873/anticanres.14988
You have access
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
YUSUKE NIISATO, TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, TOSHIKI MASUISHI, ATSUO TAKASHIMA, YOSUKE KUMEKAWA, TAKESHI KAJIWARA, KENTARO YAMAZAKI, TAITO ESAKI, AKITAKA MAKIYAMA, TADAMICHI DENDA, YUKIMASA HATACHI, TAKESHI SUTO, NAOTOSHI SUGIMOTO and YASUHIRO SHIMADA

Anticancer Research April 2021, 41 (4) 2203-2207; DOI: https://doi.org/10.21873/anticanres.14996
You have access
Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer
MASATSUNE SHIBUTANI, HISASHI NAGAHARA, TATSUNARI FUKUOKA, YASUHITO ISEKI, EN WANG, YUKI OKAZAKI, SHINICHIRO KASHIWAGI, KIYOSHI MAEDA, KOSEI HIRAKAWA and MASAICHI OHIRA

Anticancer Research July 2020, 40 (7) 4157-4163; DOI: https://doi.org/10.21873/anticanres.14415
You have access
Pretreatment Neutrophil–to–Lymphocyte Ratio Predicts Survival After TAS-102 Treatment of Patients With Metastatic Colorectal Cancer
AKIHISA MATSUDA, TAKESHI YAMADA, SATOSHI MATSUMOTO, NOBUYUKI SAKURAZAWA, YOUICHI KAWANO, ERIKO SHINOZUKA, KUMIKO SEKIGUCHI, HIDEYUKI SUZUKI and HIROSHI YOSHIDA

Anticancer Research August 2019, 39 (8) 4343-4350; DOI: https://doi.org/10.21873/anticanres.13602
You have access
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer
MICHIO KIMURA, EISEKI USAMI, HITOMI TERAMACHI and TOMOAKI YOSHIMURA

Anticancer Research February 2019, 39 (2) 1029-1034; DOI: https://doi.org/10.21873/anticanres.13209
You have access
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer
YOICHIRO YOSHIDA, RYOHEI SAKAMOTO, RYUJI KAJITANI, TARO MUNECHIKA, YOSHIKO MATSUMOTO, AKIRA KOMONO, NAOYA AISU, KOJIMA DAIBO, FUMIHIKO KIYOMI and SUGURU HASEGAWA

Anticancer Research July 2018, 38 (7) 4367-4373; DOI: https://doi.org/10.21873/anticanres.12738
You have access
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
HIDEJIRO KAWAHARA, TAKASHI MOURI, KOTA ISHIDA, NORI MATSUMOTO, TADASHI AKIBA and KATSUHIKO YANAGA

Anticancer Research April 2018, 38 (4) 2419-2422;
You have access
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
TOSHINORI SUEDA, DAISUKE SAKAI, TOSHIHIRO KUDO, TAKASHI SUGIURA, HIDEKAZU TAKAHASHI, NAOTSUGU HARAGUCHI, JUNICHI NISHIMURA, TAISHI HATA, TARO HAYASHI, TSUNEKAZU MIZUSHIMA, YUICHIRO DOKI, MASAKI MORI and TAROH SATOH

Anticancer Research August 2016, 36 (8) 4299-4306;

Main menu

User menu

Search

TAS-102

Pages